[1]
K. Pondel, K. Kawałko, K. Bielewicz, A. Chmura, and A. Karaś, “Effect of glucagon-like peptide-1 (GLP-1) agonists on the example of semaglutide on the cardiovascular system and their role in the treatment of obesity”., J Educ Health Sport, vol. 12, no. 9, pp. 55–60, Aug. 2022.